Silicon Laboratories is no longer being priced as a standalone Internet of Things chip vendor. Texas Instruments agreed in early February to buy the Austin wireless specialist for $231 a share in cash, a transaction the buyer valued near $7.5 billion, and the equity has since traded as a long-dated merger stub rather than as a cycle recovery. Stockholders adopted the merger agreement at a late-April special meeting with almost no dissent among votes cast, and the United States Hart-Scott-Rodino waiting period expired in late May. What remains is foreign merger-control and investment review, including China's State Administration for Market Regulation, on a close the parties still place in the first half of 2027.
The operating company underneath that spread is healthier than it was on announcement day. Mid-year revenue reached $228 million on higher unit volumes, industrial and commercial outpaced the home and life franchise, and medical applications printed a record quarter. Gross margin climbed back into the low sixties as overhead spread over a larger wafer of shipments, and non-GAAP operating income expanded sequentially even after the company stopped giving formal guidance. GAAP results still show a loss, merger-related costs of nearly $10 million sat inside the quarter, and first-half operating cash turned negative as company-owned inventory and receivables absorbed cash even while distributors and end customers were said to be running lighter.
The investment debate is therefore not whether wireless demand recovered. It is whether remaining foreign clearances arrive in time for the stated first-half 2027 window, or whether a break sends the stock back toward a standalone multiple on a franchise that is growing again but still GAAP-unprofitable and still fabless in Asia. The cash consideration caps the upside. The residual question is how much of the recovery survives if the takeout does not.